CA-IKOTEK
Ikotek, the leading IoT original design manufacturer (ODM), announces with immediate effect the appointment of Mathi Gurusamy as its new Chief Operating Officer (COO). In his new role, Mathi will be responsible for overseeing the company's day-to-day operations, driving strategic initiatives, and contributing to Ikotek's continued growth and success.
Mathi Gurusamy brings a wealth of expertise with over 20 years of experience in the IoT sector and electronic device industry to Ikotek. Prior to joining Ikotek, Mathi held CEO and COO positions at Mobilogix and Telit for the last 15 years. Most recently, Mathi served as Telit Cinterion’s president of its IoT solutions division after the company had acquired Mobilogix in June 2022. Renowned for his adeptness in transforming start-ups into thriving enterprises, Mathi boasts a proven track record. His achievements include securing Fortune 500 companies as clients and cultivating strategic alliances with pivotal partners in the wireless industry.
With a demonstrated ability to effectively manage and drive critical business requirements, Mathi will play a pivotal role in propelling Ikotek's sustained growth and success. His robust leadership skills and strategic vision will help scale Ikotek's business objectives in the US and globally, ensuring a seamless alignment of the company’s services and delivery functions, and continue to deliver significant business impact to Ikotek’s OEM customers globally.
“We are delighted to welcome Mathi Gurusamy to Ikotek as our new COO,” commented Joe Peterson, Ikotek CEO. “His proven track record in the IoT industry and his strategic mindset make him an excellent fit for our organization. Mathi joining Ikotek is a strong endorsement and I am confident that Mathi's leadership will play a key role in advancing Ikotek's mission and ensuring our continued growth."
Mathi Gurusamy expressed his enthusiasm for joining Ikotek, stating, "I am thrilled to be part of the Ikotek team and excited about the opportunity to contribute to the company's impressive growth history. Ikotek has a strong reputation for innovation and commercial excellence across the IoT ecosystem. The ambitious growth vision and strategy is only possible with the massive investment Ikotek and its parent company Quectel has undertaken. I look forward to working with the most talented team in the industry to drive operational efficiency and deliver excellent value to our customers."
As a vital component of the Quectel family and leveraging the significant eco-system synergies of the parent company, Ikotek stands out as the only global ODM exclusively dedicated to IoT. Providing an all-encompassing suite of IoT solutions, Ikotek serves as a comprehensive one-stop-shop covering design and development, hardware construction, testing and verification, product validation, software development, manufacturing, and certification. This integrated approach ensures the delivery of top-tier products and services aimed at minimizing complexity, accelerating time to market, mitigating risks, and optimizing costs. Ikotek's commitment lies in delivering high-quality solutions that resonate with the evolving demands of the IoT landscape.
About Ikotek USA, Inc.
Headquartered in San Diego, California, Ikotek’s core focus is on the enterprise market as it looks to develop ODM solutions to take full advantage of IoT, covering technologies from cellular connectivity, including NB-IoT and 5G, to satellite connections and from well-established IT to relative newcomers such as artificial intelligence IoT (AIoT).
For more information: www.ikotek.com or LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231120698687/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom